Citigroup Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) with Buy Recommendation
Summarize this article with:
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks LGNXZ Citigroup Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right (LGNXZ) with Buy Recommendation December 09, 2025 — 08:14 pm EST Written by George Maybach for Fintel-> Fintel reports that on December 9, 2025, Citigroup initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNXZ) with a Buy recommendation.
Analyst Price Forecast Suggests 23.50% Downside As of December 6, 2025, the average one-year price target for Ligand Pharmaceuticals Incorporated - Equity Right is $0.00/share. The forecasts range from a low of $0.00 to a high of $0.00. The average price target represents a decrease of 23.50% from its latest reported closing price of $0.00 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Ligand Pharmaceuticals Incorporated - Equity Right is 161MM, a decrease of 35.80%. The projected annual non-GAAP EPS is 3.99. What is the Fund Sentiment? There are 5 funds or institutions reporting positions in Ligand Pharmaceuticals Incorporated - Equity Right. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to LGNXZ is 0.00%, an increase of 32.02%. Total shares owned by institutions decreased in the last three months by 0.00% to 425K shares. What are Other Shareholders Doing? VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 396K shares. No change in the last quarter. FSMAX - Fidelity Extended Market Index Fund holds 26K shares. No change in the last quarter. ONEQ - Fidelity Nasdaq Composite Index Tracking Stock holds 2K shares. No change in the last quarter. FNCMX - Fidelity Nasdaq Composite Index Fund holds 2K shares. No change in the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Ligand Pharmaceuticals Incorporated - Equity Right-> Find out what the Options Markets think of Ligand Pharmaceuticals Incorporated - Equity Right-> See our take on Ligand Pharmaceuticals Incorporated - Equity Right Upcoming Earnings-> More articles by this source-> Stocks mentioned LGNXZ More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.